KMT2A-r in AML represent a paradigm of epigenomic dysregulation, driving aggressive leukemogenesis through the hijacking of transcriptional machinery and sustained activation of proto-oncogenic pathways such as HOXA/MEIS1. Here, KMT2A is linked to acute myeloid leukemia.